申请人:[en]OREGON HEALTH & SCIENCE UNIVERSITY
公开号:WO2024049854A2
公开(公告)日:2024-03-07
Provided are compounds of Formula (I) wherein X is selected from the group of ethanyl, ethenyl, ethynyl, and triazinyl; R1is selected from the group of R1is selected from the group of alkyl, alkoxy, cycloalkyl, -CH2-cycloalkyl, -O- cycloalkyl, halogen, haloalkyl, OH, and CN; and R2is a ring moiety selected from the group of imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, phenyl, and pyridinyl, each optionally substituted; for use as inhibitors against native BCR-ABL kinase protein and clinically important BCR-ABL mutations such as T315I, F317L, E255K and Y253F for the treatment of diseases that include chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML).